Course Description

Granulation, Tabletting and Capsule Technology

August 10-13, 2015
Burlingame, CA

Course Offering 1508-201
Course ID 541

In-Person Course

Who Should Attend?
This broadly based course is intended for all scientists and technologists concerned with the development and processing of tablets, capsules and similar products, and with related drug regulatory affairs. Those having some basic knowledge of the manufacturing and assessment process with a desire to understand and apply the underlying principles that deliver performance will benefit greatly.

The material will be presented in such a way as to be of value to a varying level of expertise. This course will especially benefit those in:
  • Quality Assurance
  • Marketing
  • Validation
  • Purchasing
  • R&D
  • Regulatory Affairs
  • Manufacturing/Production
  • Engineering Support

Note: Persons seeking an in-depth treatment of only one or two of the major topics of this broadly based program may wish to consider alternative, more specialized courses offered by CfPA in this area of technology.

Course Description
The main aim of this course is to review the science relating to tabletted and encapsulated pharmaceutical products. The course begins with a consideration of raw material testing and the basic aspects of powder and granulation technology, progresses through formulation of solid dosage forms to manufacturing processes and equipment including scale-up and technology transfer. The program concludes with key aspects of the evaluation of finished products and the regulatory constraints that must be considered at each stage.

Formal sessions of the course are supplemented with informal discussion periods between lecturers and course participants and problem-solving sessions are held on both an open and private basis.

Course Director
Dr. Cecil W. Propst; Research Fellow, SPI Pharma, Grand Haven

Dr. Cecil W. Propst is a Research Fellow for SPI Pharma, a processor of a variety of specialty ingredients for the food, drug, cosmetic and related industries. He was Director of R&D (Grand Haven site) at SPI Pharma until semi retirement in 2015. He served as Director of Quality Assurance and Technical Services at Fleming and Company, and before that, President of Manufacturing Chemists. His duties included system design, product and process development and regulatory affairs. Previously, he served as cGMP Facilities Director for the University of Maryland at Baltimore, in connection with the University’s SPAC contract with the FDA.

Dr. Propst also served as Director of Technical Development for Stellar Manufacturing; Director of Quality Compliance for SmithKline Beecham; Director, Quality Assurance for Norcliff Thayer (a Revlon Company); and Group Leader/Product Development and Manager/Quality Control for Lewis Howe Company. He also serves as a consultant in the area of product development and process investigations for the chemical, diagnostic, food, engineering and beverage industries.

Additional Faculty
Ms. Joy Joseph, Consultant to the Pharmaceutical Industry
Mr. Charles Cunningham, Technical Director, Colorcon Ltd.
Mr. Dilip Parikh, President and CEO of DPharma Group
Dr. Martin Thomas, Director, Science and Technology, Quantachrome

Venue Information
San Francisco Bay Area
Hotel information will be sent
in confirmation package